Search

Your search keyword '"van Schaik, Ron H. N."' showing total 776 results

Search Constraints

Start Over You searched for: Author "van Schaik, Ron H. N." Remove constraint Author: "van Schaik, Ron H. N."
776 results on '"van Schaik, Ron H. N."'

Search Results

4. Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD

6. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

10. CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients

11. Principles of Pharmacogenetics

18. Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan

19. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

20. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy.

21. TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma

22. Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate

23. External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium

24. Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate

25. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics

26. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics

29. External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium

30. Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma

31. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

35. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-Aand HLA-Bwith anti-epileptic drugs

36. Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model.

40. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

43. Modelling changes in the pharmacokinetics of tacrolimus during pregnancy after kidney transplantation: A retrospective cohort study

44. Genetic Polymorphism as a Possible Cause of Severe Postoperative Pain.

45. Modelling changes in the pharmacokinetics of tacrolimus during pregnancy after kidney transplantation: A retrospective cohort study.

47. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

50. Towards precision dosing of aripiprazole in children and adolescents with autism spectrum disorder: Linking blood levels to weight gain and effectiveness

Catalog

Books, media, physical & digital resources